Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Short term Debt (2023 - 2024)

Historic Short term Debt for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Q4 2024 value amounting to $2.8 million.

  • Tonix Pharmaceuticals Holding's Short term Debt rose 2000.0% to $2.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.8 million, marking a year-over-year increase of 2000.0%. This contributed to the annual value of $2.8 million for FY2024, which is 2000.0% up from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Short term Debt stood at $2.8 million for Q4 2024, which was up 2000.0% from $2.8 million recorded in Q3 2024.
  • Tonix Pharmaceuticals Holding's Short term Debt's 5-year high stood at $2.8 million during Q1 2024, with a 5-year trough of $2.4 million in Q4 2023.